職位描述
SFE主管（藥企）
崗位目的：支持營(yíng)銷系統(tǒng)銷售數(shù)據(jù)分析、銷售指標(biāo)與人員配置管理、業(yè)績(jī)跟蹤、獎(jiǎng)金方案設(shè)計(jì)、計(jì)算與分析。
主要職責(zé):
1、 日常銷售數(shù)據(jù)管理及營(yíng)銷管理制度修訂完善；
2、 銷售指標(biāo)設(shè)定與人員配置規(guī)劃工作；
3、 銷售隊(duì)伍績(jī)效分析跟蹤反饋；
4、 銷售獎(jiǎng)金方案的設(shè)計(jì)及運(yùn)用分析；
5、 其他上級(jí)領(lǐng)導(dǎo)交付的工作。
任職資格:
1、 本科及以上學(xué)歷，數(shù)學(xué)、統(tǒng)計(jì)學(xué)、管理學(xué)等相關(guān)專業(yè)；
2、 4年以上醫(yī)藥行業(yè)銷售或數(shù)據(jù)分析經(jīng)驗(yàn)，有醫(yī)藥行業(yè)管理經(jīng)驗(yàn)者優(yōu)先；
3、 熟練使用Excel、 PowerPoint、Word, 具備VBA和SPSS使用經(jīng)驗(yàn)者優(yōu)先；
4、 熟悉數(shù)據(jù)分析方法及工具，了解基礎(chǔ)的業(yè)務(wù)知識(shí)；
5、 良好的溝通能力和團(tuán)隊(duì)協(xié)作精神；
6、 具備一定的項(xiàng)目管理能力，工作細(xì)致，具有較強(qiáng)的抗壓能力。
企業(yè)簡(jiǎn)介
上海中信國(guó)健醫(yī)藥發(fā)展有限公司
上海中信國(guó)健醫(yī)藥發(fā)展有限公司為上海中信國(guó)健藥業(yè)股份有限公司全資子公司。
上海中信國(guó)健藥業(yè)股份有限公司（以下簡(jiǎn)稱“中信國(guó)健”）是由中國(guó)中信集團(tuán)有限公司旗下中信泰富有限公司投資控股的生物醫(yī)藥高新技術(shù)企業(yè)。公司自2002年創(chuàng)建以來(lái)，專注于抗體藥物的研發(fā)、中試和產(chǎn)業(yè)化，現(xiàn)已發(fā)展成為國(guó)內(nèi)抗體制藥領(lǐng)域的領(lǐng)軍企業(yè)，提供覆蓋治療腫瘤、自身免疫性疾病、抗器官移植排斥反應(yīng)等重大疾病領(lǐng)域的靶向藥物。
作為一家以研發(fā)為基礎(chǔ)的生物制藥公司，中信國(guó)健已成功構(gòu)建了抗體藥物開(kāi)發(fā)和產(chǎn)業(yè)化平臺(tái)并掌握核心技術(shù)，具備持續(xù)開(kāi)發(fā)新藥的創(chuàng)新能力。公司生產(chǎn)規(guī)模位居行業(yè)前列。
Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a high-tech bio -pharmaceutical company which is co-invested and led by China International Trust and Investment Corporation (CITIC) Group. CPGJ focuses on R&D, pilot development, industrialization and commercialization of monoclonal antibody drugs. Established in 2002 and going through more than ten years of growth, CPGJ has become a leading player in China’s domestic therapeutic Mab area. It has built up the largest production capacity for monoclonal antibody drugs in China and further expansion is undergoing within CPGJ’s strategic planning. The company’s product pipeline has covered the therapeutic solutions for critical diseases in Oncology, Transplantation and Autoimmune Disorders. Its drug for rheumatic disease has maintained a leading domestic market share in the biological anti-rheumatic drugs field in China.
Dedicated to sharpening its Research & Development capability, CPGJ has successfully produced key technological know-hows for the development and industrialization of monoclonal antibody drugs. As CPGJ’s wholly owned R&D organization, Biotechnology Institute of Shanghai CP Guojian focuses on discovery and early development of therapeutic antibodies and proteins, as well as innovation of technologies and processes to support drug development. The institute has established a comprehensive technological platform with a strong capability to take a drug development program from early discovery through CMC stage.
現(xiàn)由于公司發(fā)展需要，誠(chéng)聘具有創(chuàng)新精神和成就事業(yè)理想的優(yōu)秀人才加盟。
請(qǐng)符合條件的應(yīng)聘者將中英文簡(jiǎn)歷等信息發(fā)送E-mail至：cpgjhr@cpgj-pharm.com （請(qǐng)?jiān)卩]件題目上注明應(yīng)聘職位等信息）
[展開(kāi)全文]
[收縮全文]
